Bharat Biotech will acquire a 100% equity stake of Chiron Behring Vaccines in fully cash transaction. Agreement signed on 15th February with Chiron Behring Vaccines, Ankleshwar, Gujarat, from GlaxoSmithKline.
All closing terms are intended to complete in this week. Chairman and Managing Director of Bharat Biotech Krishna Ella said, “This acquisition is strategic in helping us enhance our opportunities to achieve greater scale in tackling public health problems.”
Chiron Behring Vaccines manufactures rabies vaccines. The company was founded in 1989 and is based in Ankleshwar, India. Chiron Behring Vaccines Private Limited operates as a subsidiary of GSK. One of the largest manufacturer high-quality rabies vaccines in the world which is a WHO Pre-qualified manufacturer and eligible for supplies to UN agencies and has product registrations in more than 20 countries.
With growing demand, this acquisition will help Bharat Biotech to stronghold its present clients and increase product availability in more countries.
Bharat Biotech engages in the research, development, and manufacture of vaccines and biotherapeutics. Its products include TYPBAR, a vi polysaccharide typhoid vaccine; Revac-B+, a recombinant hepatitis-B vaccine; BIOPOLIO, a poliomyelitis vaccine; INDIRAB, a rabies vaccine; TEVAC, a tetanus vaccine; BioHib, a haemophilus influenza type b vaccine, Revac-Bmcf, a thiomersal free recombinant hepatitis-B vaccine and Scorgen, a scorpion venom anti-serum. It has market access to more than 70 countries.
WHO reports that rabbies causes tens of thousands of deaths every year, mainly in Asia and Africa and it is present on all continents, except Antarctica, with over 95% of human deaths.
